SecBot SecBot

BIAF drug pipeline

$1.65
−10.8% 1-day · Nov 20
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±4.9%
1-day, median of 5 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseCommercially Available (LDT)
Time to marketAlready commercially available in the U.S. as a laboratory developed test (LDT) through the company's CLIA-certified lab. CMS reimbursement has been in effect since January 2024.

CyPath Lung Updated Nov 17

What to watch

CyPath Lung is already commercial and generating revenue, so the next catalysts are commercial execution metrics (quarterly sales growth, test volumes, physician adoption) and data readouts from the large-scale longitudinal clinical study initiated in March 2026. The stock has fallen ~90% from its 52-week high and recently dipped after Q3 earnings, making sustained sales acceleration the key swing factor for the shares.

Bull case
  • CyPath Lung is a noninvasive, sputum-based test with strong published performance (92% sensitivity, 87% specificity, 88% accuracy) for early-stage lung cancer detection.
  • Commercial momentum is accelerating: sales more than doubled through Q3 2026 year-over-year, with a record 235 tests performed in October 2026.
  • CMS has a final payment determination in place (effective January 2024), providing a clear Medicare reimbursement pathway.
Bear case
  • Revenue remains tiny ($1.07M in Q3 2026) and the company is unprofitable, requiring repeated capital raises (a $4M direct offering closed in October 2026).
  • The stock has lost roughly 90% from its 52-week high of $80.70, trading near $1.90, signaling severe market skepticism.
  • Analyst consensus is weak: 0 buy, 3 hold, 1 sell, 2 strong sell (March 2026 snapshot).

Other drugs in filings and trials

no drug report yet
  • AUKELSO Last: Approval · Sep 16, 2025
  • KIRSTY Last: Approval · Jul 15, 2025
  • JOBEVNE Last: Approval · Apr 9, 2025
  • YESINTEK Last: Approval · Nov 29, 2024
  • YESAFILI Last: Approval · May 20, 2024

Past FDA events & how the stock moved

5 events
DateDrugEvent1 day5 days
Sep 16, 2025AUKELSOApproval−47.7%−53.6%
Jul 15, 2025KIRSTYApproval+15.3%+19.5%
Apr 9, 2025JOBEVNEApproval−4.0%−19.4%
Nov 29, 2024YESINTEKApproval−3.4%−11.1%
May 20, 2024YESAFILIApproval+4.9%+12.4%